OSI Pharmaceuticals

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Retrieved on: 
Tuesday, December 12, 2023
Senior, Therapy, Joseph Talamo, CFO, Intensity, Biotechnology, Patient, Caladrius Biosciences, Market for corporate control, Controller, Cancer, CPA, BBA, Hofstra University, OSI Pharmaceuticals, Pharmaceutical industry

SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than 25 years of leadership experience in the biotechnology space, Mr. Talamo most recently served as Senior Vice President and Chief Financial Officer of HiberCell. Mr. John Wesolowski will remain as the Company's Principal Accounting Officer and Controller. 

Key Points: 
  • An accomplished executive with more than 25 years of leadership experience in the biotechnology space, Mr. Talamo most recently served as Senior Vice President and Chief Financial Officer of HiberCell.
  • Mr. John Wesolowski will remain as the Company's Principal Accounting Officer and Controller.
  • "I am delighted to welcome Joe to Intensity, his wealth of experience as a biotechnology executive and track record of success in leading financial operations will prove invaluable as we transition to a late-stage clinical company," said Lewis H. Bender , President and Chief Executive Officer of Intensity.
  • As CFO, Mr. Talamo will develop and implement Intensity's financial strategies and lead financial reporting, finance corporate development, strategy and investor relations efforts while supporting the Company's overall business goals.

PIC Therapeutics Expands its Team with the Addition of Translational Biology Oncology Leader, Richard Gedrich, PhD as Chief Development Officer

Retrieved on: 
Thursday, September 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Tissue, GSK plc, Drug development, OSI Pharmaceuticals, Therapy, Breast, Doctor of Philosophy, Rich, Patient, Cancer, Drug discovery, PIC, Bayer, Pharmaceutical industry, Publius Cornelius Arvina

PIC Therapeutics (PIC), an innovative pre-clinical stage biotech company focused on developing oncology therapeutics that modulate protein translation, today announced that Richard Gedrich, PhD has joined its Leadership Team as Chief Development Officer.

Key Points: 
  • PIC Therapeutics (PIC), an innovative pre-clinical stage biotech company focused on developing oncology therapeutics that modulate protein translation, today announced that Richard Gedrich, PhD has joined its Leadership Team as Chief Development Officer.
  • Prior to joining PIC, Rich was Executive Director at Arvinas, a leading protein degrader platform company, where he led oncology translational strategy for multiple clinical assets from pre-clinical to later-stage clinical development.
  • “Rich’s Translational Strategy experience will play a pivotal role in advancing our protein translational regulators program to the clinic.
  • I am eager to work with the team and contribute my experience as PIC transitions into a clinical-stage company.”

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

Retrieved on: 
Thursday, September 14, 2023
OSI Pharmaceuticals, Chronic kidney disease, Biotechnology, Allergan, Finance, Amicus Therapeutics, Fairleigh Dickinson University, Strategic management, Hypertension, Sequah Medicine Company, Massachusetts Institute of Technology, Patient, Flare, Chemical engineering, Pace University, Harvard Business School, Intercept Pharmaceuticals, Astellas Pharma, Growth, Therapy, CKD, Daphne, Pharmaceutical industry, Management

In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.

Key Points: 
  • In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.
  • “We are excited to have Daphne and Glenn join our Board and support Mineralys' efforts to develop innovative medicines aimed to improve the lives of patients with cardiorenal disorders.
  • Ms. Karydas has previously served on the boards of directors at Elicio Therapeutics, LogicBio Therapeutics, Inc., and Eucrates Biomedical Acquisition Corp. Ms. Karydas received a B.A.
  • Mr. Sblendorio also serves as a member of the board of directors of Intercept Pharmaceuticals, Inc. and as a member of the board of directors of Amicus Therapeutics, Inc. Mr. Sblendorio received his B.B.A.

ImmunityBio Names Enrique Diloné as Chief Technology Officer

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Vaccine, OSI Pharmaceuticals, Therapy, Doctor of Philosophy, CMC, Bachelor of Arts, Licensure, Bladder cancer, Congenital muscular dystrophy, Chemistry, Patient, Harvard Business School, Eyetech, Quality control, Growth, Amicus Therapeutics, FDA, Seton Hall University, Pharmaceutical industry, New York University, ImmunityBio COVID-19 vaccine

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer.

Key Points: 
  • ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer.
  • Diloné’s career spans more than 30 years of chemistry, manufacturing and controls (CMC) management, pharmaceutical supply chain management, and regulatory responsibilities.
  • “Enrique will play a critical role in helping us manage future growth through best-in-class manufacturing processes and supply chain and quality assurance processes that are second to none.”
    Prior to joining ImmunityBio, Diloné served as Chief Technology Officer of Prothelia, a privately held biotech company developing treatments for patients with congenital muscular dystrophy.
  • Diloné will initially work closely with Dr. Lennie Sender, who had been overseeing manufacturing as part of his role as Chief Operating Officer (COO).

Molecular Templates Announces Executive Leadership Changes

Retrieved on: 
Wednesday, August 2, 2023
Columbia University, University, René, OSI Pharmaceuticals, Therapy, Senior, Transformation/transcription domain-associated protein, BioMarin Pharmaceutical, Wharton School of the University of Pennsylvania, Biotechnology, BeiGene, Medicine, Strategic planning, Washington University in St. Louis, Bachelor of Arts in Clinical Psychology, Business administration, Hematology, Paris Descartes University, ETB (company), Wesleyan University, Regulatory affairs, Master of Business Administration, Pharmacology, Mammography, ImClone Systems, Management, Nursing, Psychology, Neuroscience, Instituto de Biologia Molecular e Celular

AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.

Key Points: 
  • AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.
  • These appointments were made to better enable Molecular Templates to execute on its clinical and corporate objectives.
  • Dr. Grace Kim joined Molecular Templates in 2022 with 20 years of experience driving investor strategy, corporate strategy, and business development.
  • These management changes will help enable us to execute efficiently in the clinic and in our corporate goals,” said Eric Poma, PhD., Chief Executive and Chief Scientific Officer of Molecular Templates.

OMass Therapeutics Expands Leadership Team with Two New Appointments

Retrieved on: 
Wednesday, August 2, 2023
CASE, GSK, UCL, Royal college, Central nervous system, University, University of London, OSI Pharmaceuticals, Senior, Oxford, Biotechnology, Pharmacognosy, University of Cambridge, ARC, Drug, GW Pharmaceuticals, Royal London Hospital, Internal medicine, Biology, AstraZeneca, Manchester Metropolitan University, Psoriasis, Development, UCB, Shire (pharmaceutical company), Weapon Shop de Omasse, Novartis, DMPK, Toxicology, Imperial College London, MRCP, NHS, Rare, Therapy, Membership of the Royal Colleges of Physicians of the United Kingdom, Safety, Barts and The London School of Medicine and Dentistry, Management, Pharmaceutical industry, Pharmacology, Pfizer

Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.

Key Points: 
  • Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.
  • “Both Peter and Julia have a huge amount of experience in taking programs from preclinical through to clinical development and I am hugely excited about what they will bring to the OMass team,” said Ros Deegan, CEO of OMass Therapeutics.
  • “With our solid financial backing and new expanded facilities, we are growing our team strategically as we advance our pipeline of exciting early-stage assets in immunology and rare diseases.
  • In her most recent role at Kalvista Pharmaceuticals, she was responsible for strategy, leadership, recruitment and management of the non-clinical safety assessment team, leading toxicology, safety pharmacology and DMPK functions.

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

Retrieved on: 
Tuesday, July 18, 2023
University, OSI Pharmaceuticals, William Blair & Company, Cancer, Research, Saint John's University, CAR, Syracuse University, Business administration, Wedbush Securities, Patient, Wells Fargo, Growth, Master of Business Administration, Cornell University, Pharmaceutical industry, Filippo, Science

LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.

Key Points: 
  • LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.
  • Mr. Petti has also been named as a member of Leucid Bio's Board of Directors.
  • Most recently, Mr. Petti was Chief Executive Officer and Chief Financial Officer of Celyad Oncology SA, a biotechnology company focused on CAR-T cell therapies for cancer.
  • Filippo Petti, newly appointed Chief Executive Officer, added: "Leucid's unique approach to the field of CAR-T has tremendous potential to help cancer patients around the world.

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

Retrieved on: 
Tuesday, July 18, 2023
University, OSI Pharmaceuticals, William Blair & Company, Cancer, Research, Saint John's University, CAR, Syracuse University, Business administration, Wedbush Securities, Patient, Wells Fargo, Growth, Master of Business Administration, Cornell University, Pharmaceutical industry, Filippo, Science

LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.

Key Points: 
  • LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.
  • Mr. Petti has also been named as a member of Leucid Bio's Board of Directors.
  • Most recently, Mr. Petti was Chief Executive Officer and Chief Financial Officer of Celyad Oncology SA, a biotechnology company focused on CAR-T cell therapies for cancer.
  • Filippo Petti, newly appointed Chief Executive Officer, added: "Leucid's unique approach to the field of CAR-T has tremendous potential to help cancer patients around the world.

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 13, 2023
PASC, Biotechnology, Science, NCI, Infection, Blood, Pfizer, Government, Mpox, Publication, COVID-19, NIH, Safety, ICU, Interest, NAMSA, OSI Pharmaceuticals, UCSF Medical Center, Consolidated, Patient, Biochemistry, Medtech, CSO, Clinical trial, Metastasis, University, Research, University of Waterloo, University of Alberta, Virology, Organic chemistry, Syntex, ATM, Exosome, Plasma, Lung cancer, Internet, SAN, EST, COVID, Biophysics, Drug discovery, Cancer, Doctor of Philosophy, MD, Pharmaceutical industry, Vaccine, Cryptocurrency

SAN DIEGO, Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.

Key Points: 
  • SAN DIEGO, Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.
  • Financial Results for the Third Quarter Ended December 31, 2022
    As of December 31, 2022, Aethlon Medical had a cash balance of approximately $17.5 million.
  • The Company will hold a conference call today, Monday, February 13, 2022, at 4:30 p.m. EST to review financial results and recent corporate developments.
  • Interested parties without internet access or unable to pre-register may dial in by calling:
    All callers should ask for the Aethlon Medical, Inc. conference call.

CDR-Life Announces the Appointment of Nicole Onetto, MD, MSc, to Board of Directors

Retrieved on: 
Thursday, December 8, 2022
Roche, Breast cancer, ImmunoGen, Pediatrics, Master of Science, Acquisition, BMS, OSI Pharmaceuticals, Partnership, Bristol Myers Squibb, Ovarian cancer, YM Biosciences, Safety, University, Cancer, Biotechnology, ZymoGenetics, Ontario Institute for Cancer Research, Doctor of Philosophy, Genentech, MD, Geographic atrophy, MHC, Drug development, Severe cognitive impairment, Therapy, Gilead Sciences, Boehringer Ingelheim, Hematology, Senior, Patient, Fine chemical, Pharmaceutical industry, Medicine, Paclitaxel, Pharmacology

We are very pleased to welcome Dr. Nicole Onetto to our Board.

Key Points: 
  • We are very pleased to welcome Dr. Nicole Onetto to our Board.
  • Dr. Onetto previously worked in senior management positions at Bristol Myers Squibb (BMS), Nexstar Pharmaceuticals, and Gilead Sciences.
  • Dr. Onetto holds a medical degree from the University of Paris and a Master of Pharmacology from the University of Montréal.
  • CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide.